Fundamental Data for MGRM

MONOGRAM B(NSDQ:MGRM)

Monogram develops and commercializes innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. The Company''s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. Monogram''s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics.

# Employees: 2835

Address: 345 Oyster Point Blvd,South San Francisco,AK,USA

Phone: 650-635-1100

Fax: 650-635-1111

Website: www.monogrambio.com

Email:

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

William D. Young (Chrmn.; C.E.O.; Dir.)

Alfred G. Merriweather (Sr.V.P.; C.F.O.)

Kathy L. Hibbs (Sr.V.P.; Gen. Counl.)

William J. Welch (Sr.V.P.; Chief Commercial Off.)

Michael P. Bates M.D. (V.P. Clinical Research,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 3/31/2009

Next Earnings Date(Expected): 7/31/2009

Mean EPS (Next Qtr): ($0.19)

Mean EPS (Year): ($0.80)

Mean Estimate(Long Term): $15.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 5

Shares Performance

Period	MGRM	Compare to S&P
YTD	74.23 %	59.37 %
4 Weeks	0.00 %	-9.22 %
12 Weeks	110.70 %	98.27 %

Shares Information

Analyst Coverage: Y

Avg Volume: 245831

Shares Outstanding: 23M

Market Cap: $0.10B

52 Week High: $7.20

52 Week Low: $1.61

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 11/4/2008 MGRM split by factor of 0.170

Earnings Performance

EPS Growth in Last Quarter: -73.33 %

EPS Growth in Last Year: -333.42 %

Sales Growth in Last Quarter: 5.73 %

Sales Growth in Last Quarter: -6.89 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 1.730